{"id":"prednisone-cytarabine-vincristine-mercaptopurine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone provides anti-inflammatory and immunosuppressive effects. Cytarabine is a cytidine analog that inhibits DNA synthesis. Vincristine is a vinca alkaloid that disrupts microtubule formation and mitotic spindle function. Mercaptopurine is a purine analog that interferes with nucleotide metabolism. Together, these agents target leukemic blasts through complementary cytotoxic and cell cycle-disrupting pathways.","oneSentence":"This combination chemotherapy regimen suppresses leukemic cell proliferation through multiple mechanisms: corticosteroid immunosuppression, cytarabine-induced DNA damage, vincristine-mediated microtubule disruption, and mercaptopurine purine antagonism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:30:03.554Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL) in pediatric patients"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05157971","phase":"PHASE1","title":"Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-17","conditions":"B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT02523976","phase":"PHASE2","title":"Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2015-08-01","conditions":"Acute,Leukemia, Lymphoid","enrollment":30},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":160},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT01371630","phase":"PHASE1, PHASE2","title":"Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-08-26","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt-Like Lymphoma With 11q Aberration","enrollment":276},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT00136435","phase":"PHASE2","title":"A Study in Adults With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2002-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":"Leukemia","enrollment":27},{"nctId":"NCT01920737","phase":"PHASE2","title":"A Novel \"Pediatric-Inspired\" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08-07","conditions":"Leukemia","enrollment":39},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT06882057","phase":"PHASE2, PHASE3","title":"Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":3000},{"nctId":"NCT05032183","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":"Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT05660473","phase":"PHASE2","title":"Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-08-01","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":100},{"nctId":"NCT02420717","phase":"PHASE2","title":"Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-15","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":11},{"nctId":"NCT03384654","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-14","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":47},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT05959720","phase":"","title":"Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-09-05","conditions":"Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality","enrollment":180},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT05303792","phase":"PHASE2","title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-09","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":68},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":"Lymphoblastic Lymphoma, Childhood","enrollment":683},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":78},{"nctId":"NCT03488225","phase":"PHASE2","title":"Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-28","conditions":"Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":4},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT04845035","phase":"PHASE2","title":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT00002514","phase":"PHASE3","title":"Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-07","conditions":"Leukemia","enrollment":1929},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":600},{"nctId":"NCT04773366","phase":"PHASE3","title":"A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol","status":"RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2018-07-01","conditions":"Langerhans Cell Histiocytosis","enrollment":200},{"nctId":"NCT03564470","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic","enrollment":120},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT01117441","phase":"PHASE3","title":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-06","conditions":"Leukemia","enrollment":6136},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT02776605","phase":"PHASE2","title":"Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2016-06","conditions":"ALL","enrollment":30},{"nctId":"NCT01156883","phase":"NA","title":"Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-04","conditions":"Leukemia","enrollment":76},{"nctId":"NCT00075725","phase":"PHASE3","title":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-12-29","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":3154},{"nctId":"NCT00671034","phase":"PHASE3","title":"Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-07-21","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":166},{"nctId":"NCT00866307","phase":"PHASE1","title":"Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-23","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":104},{"nctId":"NCT00003650","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"1997-02","conditions":"Lymphoma","enrollment":179},{"nctId":"NCT00137111","phase":"PHASE3","title":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2000-07-08","conditions":"Lymphoblastic Leukemia, Acute","enrollment":501},{"nctId":"NCT00720109","phase":"PHASE2, PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":63},{"nctId":"NCT00853008","phase":"PHASE4","title":"Treatment of High Risk Adult Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2003-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT02036489","phase":"PHASE4","title":"Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2008-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":107},{"nctId":"NCT03390387","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2015-11","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":4000},{"nctId":"NCT00004228","phase":"PHASE3","title":"Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-06","conditions":"Lymphoma","enrollment":393},{"nctId":"NCT00550992","phase":"NA","title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","status":"UNKNOWN","sponsor":"Dutch Childhood Oncology Group","startDate":"2006-01","conditions":"Leukemia","enrollment":445},{"nctId":"NCT00968253","phase":"PHASE1, PHASE2","title":"RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11","conditions":"Leukemia, Acute Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT03564704","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT03553238","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic","enrollment":70},{"nctId":"NCT02419469","phase":"PHASE2","title":"Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-11-13","conditions":"Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1},{"nctId":"NCT02451774","phase":"PHASE2, PHASE3","title":"Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction","status":"UNKNOWN","sponsor":"Ramón Óscar González-Ramella, Ph.D","startDate":"2015-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":44},{"nctId":"NCT02660762","phase":"PHASE2","title":"Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Leukaemia,Lymphoblastic","enrollment":100},{"nctId":"NCT00973752","phase":"PHASE2","title":"Treatment of Older Adults With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-08","conditions":"Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT00002744","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-05","conditions":"Leukemia","enrollment":1970},{"nctId":"NCT00003700","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1999-01","conditions":"Leukemia","enrollment":163},{"nctId":"NCT00002766","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1996-03","conditions":"Leukemia, Lymphoma","enrollment":170},{"nctId":"NCT00526175","phase":"PHASE4","title":"LAL-BR/2001: Study Treatment to Low Risk ALL","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2001-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":150},{"nctId":"NCT00187057","phase":"NA","title":"Study for Treatment of Cancer in Children With Ataxia-telangiectasia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2002-09","conditions":"Ataxia-Telangiectasia","enrollment":6},{"nctId":"NCT00109837","phase":"PHASE2","title":"S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-04","conditions":"Leukemia","enrollment":79},{"nctId":"NCT00002665","phase":"PHASE2","title":"SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1995-07","conditions":"Leukemia, Neutropenia, Thrombocytopenia","enrollment":50},{"nctId":"NCT00613457","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2000-09","conditions":"Leukemia","enrollment":2039},{"nctId":"NCT00003783","phase":"PHASE2","title":"Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-03","conditions":"Leukemia","enrollment":36},{"nctId":"NCT00002618","phase":"PHASE3","title":"Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1994-12","conditions":"Lymphoma","enrollment":242},{"nctId":"NCT00002785","phase":"PHASE2","title":"Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-07","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00184041","phase":"PHASE2","title":"Intensified Post Remission Therapy Containing PEG-Asparaginase","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2004-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":47},{"nctId":"NCT01358253","phase":"PHASE4","title":"Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2010-12","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT00005603","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-03","conditions":"Leukemia","enrollment":276},{"nctId":"NCT00002756","phase":"PHASE2","title":"Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-06","conditions":"Leukemia","enrollment":221},{"nctId":"NCT01005758","phase":"PHASE2","title":"Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2009-01","conditions":"Leukemia","enrollment":180},{"nctId":"NCT00002812","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-09","conditions":"Leukemia","enrollment":2078},{"nctId":"NCT00002700","phase":"PHASE3","title":"Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1995-08","conditions":"Leukemia, Lymphoma","enrollment":392},{"nctId":"NCT01230983","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-06","conditions":"Cardiac Toxicity, Leukemia, Lymphoma","enrollment":573},{"nctId":"NCT00430118","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2000-07","conditions":"Leukemia","enrollment":4559},{"nctId":"NCT00016302","phase":"NA","title":"Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":"T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT00136084","phase":"PHASE3","title":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2002-08","conditions":"Leukemia, Myelocytic, Acute","enrollment":238},{"nctId":"NCT01665001","phase":"PHASE2","title":"Personalized Therapy of Precursor Lymphoid Neoplasms","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice","startDate":"2012-08","conditions":"Precursor Lymphoid Neoplasms","enrollment":200},{"nctId":"NCT00019409","phase":"PHASE3","title":"Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1999-10","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00018954","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1992-10","conditions":"Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00187005","phase":"PHASE3","title":"Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"1998-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":53},{"nctId":"NCT00526305","phase":"PHASE4","title":"LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2000-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT00764907","phase":"PHASE3","title":"Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"University Hospital, Motol","startDate":"2002-11","conditions":"Leukemia","enrollment":4000},{"nctId":"NCT00494897","phase":"PHASE4","title":"PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"1996-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":374},{"nctId":"NCT00187122","phase":"NA","title":"Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"1993-03","conditions":"Lymphoblastic Lymphoma","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prednisone+Cytarabine+vincristine+Mercaptopurine","genericName":"Prednisone+Cytarabine+vincristine+Mercaptopurine","companyName":"Shanghai Children's Medical Center","companyId":"shanghai-children-s-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination chemotherapy regimen suppresses leukemic cell proliferation through multiple mechanisms: corticosteroid immunosuppression, cytarabine-induced DNA damage, vincristine-mediated microtubule disruption, and mercaptopurine purine antagonism. Used for Acute lymphoblastic leukemia (ALL) in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}